Sanofi
NASDAQ:SNYDrug Manufacturers - General
-$0.31 today
- Market cap
- $113.15B
- Beta
- 0.28
- P/E (TTM)
- 8.5
- EPS (TTM)
- $8.60
- Dividend yield
- 5.62%
Volume 2.32M
Average 2.78M
SNY Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
SanofiNASDAQ: SNY
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 58.7% from a year ago
Cash & equivalents stood at €6.35B at the end of Q2 FY2026, down 58.7% from a year earlier and up 14.5% from the prior quarter. Over 3 fiscal years it compounded at -15.6% a year.
Context
- Cash & equivalents amounted to 4.9% of total assets at the end of Q2 FY2026, down 7.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -58.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
EUR · from the balance sheet
- Latest · FY2025
- 7.66B EUR
- Year-over-year change
- +2.9%
- 4-year CAGR
- -6.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.66B | +2.9% |
| FY2024 | 2024-12-31 | 7.44B | -14.6% |
| FY2023 | 2023-12-31 | 8.71B | -31.6% |
| FY2022 | 2022-12-31 | 12.74B | +26.1% |
| FY2021 | 2021-12-31 | 10.1B | — |
Cash & Equivalents vs competitors
How SNY compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -58.7% is the lowest of 11, against a peer median of -8.6%.
- Cash & equivalents amounts to 4.9% of total assets for SNY, versus a peer median of 6.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 44.48B DKK | +141.3% | +27.9% | 7.5% | |
| Jun 2026 | $13.99B USD | +74.3% | +6.2% | 14.6% | |
| Jun 2026 | $8.89B USD | +163.3% | +51.3% | 6.2% | |
| Jun 2026 | $8.72B USD | -30.8% | +3.8% | 10.0% | |
| Sep 2026 | $7.92B USD | -2.7% | -2.5% | 6.6% | |
| Jun 2026 | $7.62B USD | +14.4% | +15.0% | 6.2% | |
| Jun 2026 | $6.85B USD | -14.5% | +4.7% | 5.3% | |
| Jun 2026 | €6.35B EUR | -58.7% | -15.6% | 4.9% | |
| Jun 2026 | $3.18B USD | -38.2% | +11.8% | 6.4% | |
| Jun 2026 | £3.09B GBP | -37.4% | -3.1% | 5.0% | |
| Jun 2026 | $976M USD | -40.4% | +40.0% | 0.5% | |
| Peer median (excluding SNY) | — | -8.6% | +9.0% | 6.3% | |
Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10.1B | 12.74B | 8.71B | 7.44B | 7.66B |
| Short-term Investments | 0 | 0 | 0 | 486M | 810M |
| Net Receivables | 9.79B | 10.75B | 11.04B | 10.63B | 11.05B |
| Inventory | 8.72B | 8.96B | 9.67B | 9.43B | 10.21B |
| Other Current Assets | 1.35B | 870M | 471M | 13.71B | 307M |
| Total Current Assets | 30.56B | 34.03B | 30.66B | 42.59B | 30.95B |
| Property, Plant & Equipment (Net) | 11.98B | 11.68B | 11.81B | 11.6B | 11.51B |
| Goodwill | 48.06B | 49.89B | 49.4B | 43.38B | 41.3B |
| Intangible Assets | 21.41B | 21.64B | 24.32B | 22.63B | 26.26B |
| Long-term Investments | 2.91B | 3.22B | 3.26B | 3.26B | 6.61B |
| Tax Assets | 4.6B | 5.38B | 6.43B | 7.97B | 8.61B |
| Other Non-current Assets | 731M | 882M | 588M | 1.37B | 1.56B |
| Total Non-current Assets | 89.68B | 92.7B | 95.81B | 90.21B | 95.85B |
| Total Assets | 120.24B | 126.72B | 126.46B | 132.8B | 126.81B |
| Account Payables | 6.18B | 6.81B | 7.33B | 7.55B | 7.36B |
| Short-term Debt | 3.45B | 4.45B | 2.32B | 4.21B | 4.34B |
| Tax Payables | 309M | 574M | 597M | 1.13B | 0 |
| Deferred Revenue | 319M | 264M | 0 | 0 | 0 |
| Other Current Liabilities | 10.61B | 11.86B | 11.57B | 15.13B | 14.69B |
| Total Current Liabilities | 21.3B | 23.96B | 24.19B | 29.16B | 28.35B |
| Long-term Debt | 17.12B | 14.86B | 14.35B | 11.79B | 14.25B |
| Deferred Tax Liabilities | 1.62B | 1.84B | 1.86B | 2.17B | 1.67B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 9.34B | 9B | 9.96B | 10.18B | 9.37B |
| Total Non-current Liabilities | 29.92B | 27.61B | 27.92B | 25.78B | 26.75B |
| Total Liabilities | 51.21B | 51.57B | 52.11B | 54.94B | 55.1B |
| Common Stock | 2.53B | 2.52B | 2.53B | 2.53B | 2.44B |
| Retained Earnings | 63.01B | 66.73B | 67.5B | 0 | 0 |
| Accumulated OCI | 3.55B | 6.11B | 4.88B | 70.56B | 64.44B |
| Other Stockholders Equity | 0 | 0 | 0 | 5.26B | 5.57B |
| Minority Interest | 350M | 368M | 313M | 350M | 334M |
| Total Equity | 69.03B | 75.15B | 74.35B | 77.86B | 71.71B |
| Total Debt | 22.41B | 21.21B | 18.7B | 17.91B | 20.33B |
| Net Debt | 12.32B | 8.48B | 9.99B | 10.47B | 12.67B |
Sanofi
NASDAQ:SNY
Intrinsic Alpha fair value
Locked
Current Price
$47.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.